Levatik

Vardenafil, the active ingredient in Levatik, is a phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of erectile dysfunction in adult men, helping to achieve and maintain an erection when sexual stimulation occurs.

GNH USA supplies Levatik as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Levatik (vardenafil) is used to treat conditions related to the nitric‑oxide/cGMP pathway that affect male sexual function.

- Erectile dysfunction (ED): improves the ability to achieve and sustain an erection sufficient for sexual activity. - Diabetic‑associated erectile dysfunction: enhances erectile response in men whose condition is linked to diabetes. - Psychogenic erectile dysfunction: assists men whose erectile issues are primarily psychological in origin.

Vardenafil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Flushing: warmth and redness of the face or upper chest. - Dyspepsia: indigestion or upset stomach. - Nasal congestion: stuffy nose or runny nose. - Back pain: muscle discomfort, typically transient. - Visual changes: blurred vision or color tinge.

Serious or Rare Side Effects: - Priapism: prolonged erection lasting more than four hours, requiring emergency care. - Sudden vision loss: abrupt loss of vision in one or both eyes, possibly indicating non‑arteritic anterior ischemic optic neuropathy. - Sudden hearing loss: rapid decrease or loss of hearing, sometimes accompanied by tinnitus. - Severe hypotension: dangerous drop in blood pressure, especially when combined with nitrates. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before prescribing Levatik, clinicians should consider several precautionary measures to ensure patient safety.

- Cardiovascular assessment: evaluate for recent myocardial infarction, unstable angina, or severe heart failure. - Nitrate therapy: avoid concurrent use due to risk of profound hypotension. - Liver impairment: use with caution and consider dose adjustment in moderate to severe hepatic dysfunction. - Alcohol consumption: limit excessive intake as it may increase side‑effects. - Visual or auditory symptoms: discontinue if sudden loss of vision or hearing occurs. - Store at ambient temperature: keep in the original container, protect from moisture and light, and store below 25 °C.

Vardenafil can interact with other medicines, and the significance of the interaction determines the recommended management.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin, isosorbide dinitrate): may cause severe hypotension. - Guanylate cyclase stimulators (e.g., riociguat): risk of additive blood‑pressure lowering effects. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase vardenafil plasma levels.

Moderate Interactions (Monitor Closely): - Alpha‑blockers (e.g., doxazosin, tamsulosin): may cause additive hypotensive effects; start with low dose. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce vardenafil efficacy. - Other PDE5 inhibitors: concurrent use increases risk of adverse events and should be avoided. - Antihypertensive agents: monitor blood pressure for additive effects.